A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia.
Sandip Pravin PatelMegan K D OthusYoung Kwang ChaeMichael J DennisSarah GordonDavid G MutchWolfram E SamlowskiWilliam R RobinsonElad SharonChristopher RyanGabby LopezMelissa PletsCharles David BlankeRazelle KurzrockPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Ipilimumab plus nivolumab demonstrated efficacy in chemotherapy-refractory GTN, an ultra-rare cancer affecting young women. Three out of four patients achieved ongoing objective responses with a reasonable safety profile at 6-11+ months.
Keyphrases
- phase ii
- clinical trial
- open label
- end stage renal disease
- phase iii
- newly diagnosed
- ejection fraction
- pregnant women
- chronic kidney disease
- weight gain
- high resolution
- prognostic factors
- peritoneal dialysis
- papillary thyroid
- radiation therapy
- squamous cell carcinoma
- locally advanced
- patient reported outcomes
- body mass index
- placebo controlled
- rectal cancer
- birth weight
- childhood cancer
- preterm birth